A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 1236 (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms CYBER
- 07 May 2009 Actual initiation date changed from 1 Jan 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 07 May 2009 Planned end date changed from 1 Nov 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 02 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.